Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Clinical Trial Approved Through New EU Portal

Executive Summary

The EU’s new trial portal and database system, which allows the submission of a single application to conduct a study across any number of EU countries, has yielded its first fruit in the form of an approval for a non-commercial Swedish clinical trial involving cardiac arrest patients.

You may also be interested in...



Time Running Out To Switch Ongoing Studies To EU Clinical Trials Regulation

Industry and academic study sponsors have called for an urgent solution to address the administrative burden and the short timeframe remaining to move their ongoing trials authorized under the EU Clinical Trials Directive to the Clinical Trials Regulation.

EU Sees Sharp Rise In Clinical Trial Applications Via New Portal

Notably more clinical trial applications were submitted to the new Clinical Trial Information System in July compared with previous months, according to new data that also shed light on how many submissions have been approved or rejected.

How The EU Is Keeping Up With Innovation In Clinical Trials

A senior EMA official says Europe has set the ball rolling on presenting a unified approach on clinical trial processes and strategic matters, and is taking steps to ensure there are no roadblocks.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel